Industry Summit

The MedCan 2022 Industry Summit will help local companies accelerate their path to market through valuable insights into exporting, innovation and education. Industry experts will be presenting the latest scientific findings and breakthrough technologies and exploring the current challenges and opportunities around the likes of cultivating, manufacturing, New Zealand regulations, export, clinical trials, prescription and investment.  

Day 1 – Industry Summit – 10 February

09:10

Meet and greet your fellow attendees in random breakout rooms in this icebreaker session.

09:20
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
Hon. Andrew Little Minister of Health, Labour Party
10:05
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?

Manu Caddie, Co-Founder, Kaihautu – Innovation and Regulation, Rua Bioscience

Carmen Doran Chief Executive Officer, Helius Therapeutics
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
11:00
11:15
Industry
Andrew Patterson Business Commentator
11:20
Industry
Carmen Doran Chief Executive Officer, Helius Therapeutics
Eva Neshat Founder and Chief Executive Officer, Elysian Pharmaceuticals & CannaPlus+
Zoë Reece Founder and CEO, Ora Pharm
Dr Dottie Clower Chief Scientific Officer, Puro
12:20
Industry

• Types of investment
• Trends
• Future of investments

Kristen Lunman Co-Founder and GM, Hatch
12:50
Industry

This presentation will highlight the commercial potential for medicinal cannabis or hemp beyond its primary use by taking a ‘whole of resource’ approach. It will outline how the Bioresource Processing Alliance and research providers can help industry partners identify high-value opportunities from low-value biological resources.

Andrew Cameron Principal Consultant, Callaghan Innovation
Anna Yallop General Manager, Bioresource Processing Alliance
14:10
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
14:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro
09:10

Meet and greet your fellow attendees in random breakout rooms in this icebreaker session.

09:20
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
Hon. Andrew Little Minister of Health, Labour Party
10:05
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?

Manu Caddie, Co-Founder, Kaihautu – Innovation and Regulation, Rua Bioscience

Carmen Doran Chief Executive Officer, Helius Therapeutics
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
11:00
11:15
Science
Imche Fourie Co-Founder & CEO, Outset Ventures
11:20
Science

• New Zealand gene bank
• different genetic technologies
• development of unique plants to those grown internationally
• Which traits to select- from disease resistance to cannabinoid profiles
• role of data management in a well-run breeding programme

Dr Anna Campbell Consultant, AbacusBio
12:20
Science
Carmen Doran Chief Executive Officer, Helius Therapeutics
Ali Seyfoddin Associate Professor of Drug Delivery and Biological Engineering Deputy Head of School, School of Science, Auckland University of Technology
14:10
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
14:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro

Day 2 – Industry Summit – 11 February

08:50
09:00

Meet and greet your fellow attendees in random breakout rooms in this icebreaker session.

09:20
Bonni Goldstein Medical Director, Canna Centers Wellness & Education
09:40
Brooke van Velden List Member, ACT Party
10:00

Research shows that being from New Zealand adds value to your brand, and that provenance matters. This session showcases the strength in brand New Zealand and  

will shed light on the value-adding opportunity for medicinal cannabis. 

  • Using New Zealand’s brand and image in the medicinal cannabis industry – how can we leverage this to increase value? 
  • Coming together and collaborating to advocate for the industry – what is the opportunity here? 
  • A view into the practical tools that the New Zealand Story group have to help 
David Downs Chief Executive Officer, New Zealand Story
11:00
  • The opportunity to develop the CBD sector in New Zealand – what are the resources available to achieve this?
  • Insights into the economic opportunity
Mitch Cuevas Pharmaceutical Director, Eqalis
11:40
  • Explaining the work currently being undertaken by Crown Research Institutes in the medicinal cannabis space
  • Advocating for the industry – a spotlight on the work taking place here

Dr Richard Newcomb, PhD Chief Scientist, Plant & Food Research
Dr Emma Bermingham Science Objective Leader Added Value Foods & Bio-based Products, AgResearch
Dr Florian Graichen GM – Forests to Biobased products, Scion
12:10

Mark Robinson, Business Innovation Advisor – Health Sector, Callaghan Innovation

13:00
  • Application process in obtaining a licence through the Medicinal Cannabis Agency – tips and tricks
    Facilitator: Andrea Eng, Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
  • EBM4CBD/THC
    Facilitators: Dr Michael Murphy MB, BS, Pharm B.Sc (Hons), Clinical Director, CannaPlus+;
    Dr Afraz Adam MBBS. FRNZCUC, Chief Medical Officer, CannaPlus+
    Extraction technologies
    Steve Tallon Team Leader, Process Engineering Group, Callaghan Innovation
  • Analysis and testing
    Facilitators: Bruce Fraser, New Zealand General Manager, Shimadzu
    Sam Dallas, Analytical Technology Technician, Hill Laboratories
14:40

  • The endocannabinoid system in animals
  • A brief history of veterinary medicinal cannabis
  • Toxicology and the THC myth
  • Local and overseas clinical trials to date
  • Market opportunities and regulatory affairs
13:00
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
13:00
Dr Michael Murphy Clinical Director, CannaPlus+
Dr Afraz Adam MBBS. FRNZCUC Chief Medical Officer, CannaPlus+
13:00
Steve Tallon Team Leader, Process Engineering Group, Callaghan Innovation
13:00
Bruce Fraser Team Leader, Process Engineering Group, Callaghan Innovation
Sam Dallas Analytical Technology Technician, Hill Laboratories
13:40
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
13:40
Dr Afraz Adam MBBS. FRNZCUC Chief Medical Officer, CannaPlus+
Dr. Michael Murphy MB, BS, Pharm B.Sc (Hons) Clinical Director, CannaPlus+
13:40
Steve Tallon Team Leader, Process Engineering Group, Callaghan Innovation
13:40
Bruce Fraser Team Leader, Process Engineering Group, Callaghan Innovation
Sam Dallas Analytical Technology Technician, Hill Laboratories